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image outcome than the surgically treated OCC patients. 
Education was also an independent factor for BIS. In OCC 
patients, facial skin sacrificed, mouth angle sacrificed, 
maxillectomy, and mandibulectomy were significantly 
associated with BIS. Using multivariate analysis, inferior 
maxillectomy and segmental mandibulectomy were the 
independent poor prognosticators of body image outcome in 
OCC patients. 
 
Conclusion: The radical surgery for head and neck cancer 
patients has a significant impact on body image, especially 
those with facial bone destruction. These findings could be 
used to guide psychosocial interventions targeting body 
image disturbance for patients with head and neck cancer. 
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Purpose or Objective: Head and neck cancer patients 
treated with chemoradiation are at risk for developing 
trismus (reduced mouth opening). Trismus is often a 
persisting side-effect and difficult to manage. It impairs 
eating, speech and oral hygiene, affecting quality of life. 
Although several studies identified the masseter muscle (MM) 
as one of the main organs at risk, currently this structure is 
rarely considered during treatment planning. Prospective 
studies for chemoradiation are lacking. The aim of our study 
was to quantify the relationship between radiation dose to 
the MM and development of radiation-induced trismus in an 
IMRT-VMAT population. 
 
Material and Methods: The 93 patients in this study 
participated in a prospective preventive exercise program to 
preserve oral functioning between 2006-2013. All received 
concomitant high-dose chemotherapy during VMAT- or IMRT-
radiotherapy (70 Gy in 35 fractions). Tumor locations were 
mainly oropharynx (37%) and hypopharynx (33%). Maximum 
interincisor mouth opening was measured before and 
approximately 10 weeks after the end of treatment. Bilateral 
delineations of the MM were available from 2 retrospective 
studies. Patients were excluded if trismus was present at 
baseline, or if gross tumor infiltration of the MM was present 
on CT evaluation. Evaluated outcomes were trismus (mouth 
opening ≤ 35 mm) and decrease in mouth opening. Logistic 
regression (using maximum likelihood) was performed. 
 
Results: At the first evaluation, 6-12 weeks post-treatment, 
fourteen patients had developed radiation-induced trismus 
(15%). On average, mouth opening decreased with 4.1 mm, or 
8.2 % relative to baseline. Mean dose to the ipsilateral MM 
was a stronger predictor for trismus than mean dose to the 
contralateral MM, as indicated by the lowest -2 log likelihood 
(Table 1). Figure 1A shows the correlation between the 
ipsilateral mean masseter dose and the relative decrease in 
mouth opening, with trismus cases indicated in red. No 
trismus cases were observed in 33 patients (35%) with a mean 
dose to the ipsilateral MM < 20 Gy. The risk of trismus in the 
other 60 patients (65%) increased with higher mean doses to 
the ipsilateral MM. Figure 1B shows the fitted NTCP curve as 
a function of the mean dose, with a TD50 of 55 Gy. The 
actual incidence (with 1 SE) of trismus cases within 5 dose 
bins is indicated as well, showing a good correspondence with 
the NTCP fit with a relatively large uncertainty in the dose 
area > 50 Gy. Patients with tumors located in the oropharynx 
were at highest risk. 
 
Conclusion: The risk of trismus can be established with the 
mean dose to the ipsilateral masseter muscle. The majority 
of head and neck cancer patients could benefit from dose 
reduction to the masseter muscles to prevent trismus, 
especially patients with a mean dose to the ipsilateral 
masseter > 20 Gy. Further development of a NTCP model 
could identify dose objectives to guide treatment planning. 
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Purpose or Objective: Oral mucositis (OM) is the most 
frequent and severe acute toxicity of chemoradiotherapy 
(CRT) in head and neck cancer (HNC) patients. In preclinical 
